Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy

Lancet Infectious Diseases

Volumn 2, Issue 8, 2002, Pages 461-471

  Thomson, Michael M ^a   Pérez Álvarez, Lucía ^a   Nájera, Rafael ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; DEVELOPING COUNTRY; EPIDEMIC; GENE TARGETING; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL GENETICS; VIRUS CHARACTERIZATION; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS RECOMBINATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 0036319711     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00343-2     Document Type: Review

References (81)

1. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates
2. pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy
3. Timing the ancestor of the HIV-1 pandemic strains
4. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes
5. HIV-1 nomenclature proposal
6. HIV-1 genetic diversity in Galicia, Spain: BG intersubtype recombinant viruses are circulating among injecting drug users
7. Identification, by analysis of near full-length sequences, of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, exhibiting a pseudotype-like virion structure
8. Molecular epidemiology of HIV type 1 infection in Portugal: High prevalence of non-B subtypes
9. Recombinant HIV sequences: Their role in the global epidemic
10. High HIV-1 genetic diversity in Cuba
11. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000
12. Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E
13. Unprecedented degree of human immunodeficiency virus type I (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa
14. Widespread circulation of a B/F intersubtype recombinant form among HIV-1-infected individuals in Buenos Aires, Argentina
15. Diversity of mosaic structures and common ancestry of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near full-length genome sequences
16. Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into Western countries
17. High proportion of unrelated HIV-1 intersubtype recombinants in the Mbeya region of southwest Tanzania
18. HIV super-infection: Rapid replacement of AE subtype by B subtype
19. Molecular epidemiology of viral infections
20. HIV-1 drug resistance in newly infected individuals
21. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-1 subjects in North-America
22. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naïve patients of the German Seroconverter Study
23. Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance
24. Patient HIV-1 strains carring the multiple nucleoside resistance mutations are cross-resistant to abacavir
25. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): Multicenter study of patients treated with RT inhibitors
26. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors
27. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility
28. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naïve individuals worldwide
29. Resistance-associated mutations virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom
30. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia)
31. Genotypic variation of HIV-1 reverse transcriptase and protease: Comparative analysis of clade C and clade B
32. Protease and RT sequences of B and non-B subtype HIV-1 viruses from Latin-America and Spain show distinct amino acid mutation patterns in treated and drug-naive patients
33. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1 infected African patients
34. HIV-1 subtype G and BG recombinant viruses in Spanish natives: Evidence of characteristic mutations in reverse transcripts and protease
35. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1
36. Determinants for the syncytium-inducing phenotype of HIV-1 subtype F isolates are located in the V3 region
37. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS
38. HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe
39. Biological characteristics of newly described HIV-1 BG recombinants in Spanish individuals
40. Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes
41. HIV-1 LTR subtype and perinatal transmission
42. Human immunodeficiency virus type I subtypes differ in disease progression
43. Effect of Human Immunodeficiency Virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda
44. Similar rate of disease progression among individuals infected with HIV-I genetic subtypes A-D
45. Clinical disease associated with HIV-1 subtype B and E infection among 2104 patients in Thailand
46. African HIV-I subtype C and rate of progression among Ethiopian immigrants in Israel
47. Evaluation of United States-licensed human immunodefciency virus immunoassays for detection of group M viral variants
48. Evaluation of a sensitive/less-sensitive testing algorith using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand
49. Comparative performance of three viral load assays on human immunodeficiency virus type 1(HIV-1) isolates representing group M (subtypes A to G) and group O:LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0
50. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
51. Prospects for vaccine protection against HIV-1 infection and AIDS
52. Quantitative analysis of serum neutralisation of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and T: Lack of direct correlation between neutralisation serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement
53. Inter- and intraclade neutralisation of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralisation serotypes but partially correspond to gp120 antigenic serotypes
54. Multivariate analysis of human immunodeficiency virus type 1 neutralisation data
55. Two antigenically distinct subtypes human immunodeficiency virus type 1: Viral genotype predicts neutralisation serotype
56. Human immunodeficiency virus type 1 neutralising antibody serotyping using serum pools and an infectivity reduction assay
57. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B
58. Cross-clade neutralisation of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
59. Regional clustering of shared neutralisation determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa
60. Characterization of sera from subjects infected with HIV-1 subtypes B and E by antibody binding and neutralisation
61. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralise several X4-, R5-, and dualtropic clade B and C primary isolates
62. Fusion-competent vaccines: Broad neutralisation of primary isolates of HIV
63. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors
64. Cñade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
65. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians
66. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development
67. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients
68. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais
69. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: Relevance to HIV-I vaccine trials in Uganda
70. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa
71. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
72. Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients
73. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain
74. Role of CD8+ lymphocyes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment
75. FIV infection of the domestic cat: An animal model for AIDS
76. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates
77. Approaches to the development of broadly protective HIV vaccines: Challenges posed by the genetic, biological and antigenic variability of HIV-1. Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee. Geneva, 21-23 February 2000
78. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya
79. The HIV vaccine pipeline, from preclinical to phase III
80. Identification of highly conserved and broadly cross-reactive HIV type I cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored vaccines